Search

Your search keyword '"Neurocysticercosis blood"' showing total 76 results

Search Constraints

Start Over You searched for: Descriptor "Neurocysticercosis blood" Remove constraint Descriptor: "Neurocysticercosis blood"
76 results on '"Neurocysticercosis blood"'

Search Results

1. Immunologic Profiling of CSF in Subarachnoid Neurocysticercosis Reveals Specific Interleukin-10-Producing Cell Populations During Treatment.

2. Mass Spectrometry Identifies Taenia solium Proteins in Sera of Patients With and Without Parenchymal Neurocysticercosis.

3. Circulating cell-free DNA as a biomarker for molecular diagnosis of Neurocysticercosis.

4. High frequency of Taenia solium antigen positivity in patients admitted for neurological disorders in the Rural Hospital of Mosango, Democratic Republic of Congo.

5. Sorting out difficulties in immunological diagnosis of neurocysticercosis: Development and assessment of real time loop mediated isothermal amplification of cysticercal DNA in blood.

6. Albendazole Sulfoxide Plasma Levels and Efficacy of Antiparasitic Treatment in Patients With Parenchymal Neurocysticercosis.

7. Neurocysticercosis serodiagnosis: mimotope-based synthetic peptide as potential biomarker.

8. The status and health burden of neurocysticercosis in Mbulu district, northern Tanzania.

9. Distinguishing neurocysticercosis epilepsy from epilepsy of unknown etiology using a minimal serum mass profiling platform.

10. [Study on diagnosis of atypical cerebral cysticercosis].

11. Treatment-Resistant Human Extraparenchymal Neurocysticercosis: An Immune-Inflammatory Approach to Cysticidal Treatment Outcome.

12. Low sensitivity and frequent cross-reactions in commercially available antibody detection ELISA assays for Taenia solium cysticercosis.

13. Soluble Fas/FasLare elevated in the serum and cerebrospinal fluid of patients with neurocysticercosis.

14. Human Glutathione S-Transferase Enzyme Gene Polymorphisms and Their Association With Neurocysticercosis.

15. Usefulness of gel filtration fraction as potential biomarker for neurocysticercosis in serum: towards a new diagnostic tool.

16. Experimental neurocysticercosis: absence of IL-4 induces lower encephalitis.

17. High Prevalence of Asymptomatic Neurocysticercosis in an Endemic Rural Community in Peru.

18. Intranasal microemulsion for targeted nose to brain delivery in neurocysticercosis: Role of docosahexaenoic acid.

19. Diethylaminoethyl (DEAE) binding fraction from Taenia solium metacestode improves the neurocysticercosis serodiagnosis.

20. Recombinant protein- and synthetic peptide-based immunoblot test for diagnosis of neurocysticercosis.

21. Three cases of imported neurocysticercosis in Northern Italy.

22. Pediatric neurocysticercosis: usefulness of antibody response in cysticidal treatment follow-up.

23. Parasite antigen in serum predicts the presence of viable brain parasites in patients with apparently calcified cysticercosis only.

24. T1-weighted dynamic contrast-enhanced MR evaluation of different stages of neurocysticercosis and its relationship with serum MMP-9 expression.

25. Epilepsy and cysticercosis in Northwest Cameroon: a serological study.

26. [In vitro effect of the S3Pvac vaccine against cysticercosis in human mononucleate cells].

29. Neurocysticercosis: is serology useful in the absence of brain imaging?

30. Human neurocysticercosis: in vivo expansion of peripheral regulatory T cells and their recruitment in the central nervous system.

31. A simple LC-MS/MS method to determine plasma and cerebrospinal fluid levels of albendazole metabolites (albendazole sulfoxide and albendazole sulfone) in patients with neurocysticercosis.

32. Immune response in symptomatic and asymptomatic neurocysticercosis.

33. Association of MMP-2 and MMP-9 with clinical outcome of neurocysticercosis.

34. Taenia solium: a two-dimensional Western blotting method combined with the use of an EST-library for the identification of immunogenic proteins recognized by sera from neurocysticercosis patients.

35. Relative seroprevalence of cysticercus antigens and antibodies and antibodies to Taenia ova in a population sample in south India suggests immunity against neurocysticercosis.

36. Bioactive molecules of Taenia solium metacestode, a causative agent of neurocysticercosis.

37. A serological study of cysticercosis in patients with HIV.

38. Detection of Taenia solium antigens and anti-T. solium antibodies in paired serum and cerebrospinal fluid samples from patients with intraparenchymal or extraparenchymal neurocysticercosis.

39. Immunodiagnosis of human neurocysticercosis using a synthetic peptide selected by phage-display.

40. Urine antigen detection for the diagnosis of human neurocysticercosis.

41. Lipid peroxidation in the cerebrospinal fluid of patients with neurocysticercosis.

42. ELISA in the evaluation of therapeutic response to albendazole in neurocysticercosis.

43. Detection of HP10 antigen in serum for diagnosis and follow-up of subarachnoidal and intraventricular human neurocysticercosis.

44. Recombinant expression of Taenia solium TS14 antigen and its utilization for immunodiagnosis of neurocysticercosis.

45. A clinico-serological study of neurocysticercosis in patients with ring enhancing lesions in CT scan of brain.

46. Management of potential neurocysticercosis in patients with HIV infection.

47. Serum and cerebrospinal fluid S100B concentrations in patients with neurocysticercosis.

48. Diagnosis of neurocysticercosis by enzyme-linked immunosorbent assay.

49. Application of synthetic 8-kD and recombinant GP50 antigens in the diagnosis of neurocysticercosis by enzyme-linked immunosorbent assay.

50. [Electroencephalograms (EEG) in 250 patients with epilepsy in a cysticercosis endemic area in Burundi].

Catalog

Books, media, physical & digital resources